Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
This study is for people in the UK who have a type of blood cancer called Chronic Lymphocytic Leukemia (CLL) and are starting treatment with a medicine called venetoclax. Doctors want to learn more about how well venetoclax works in real-life situations and how it's managed by both patients and healthcare teams. This isn't a study where you get a new or experimental drug; it's about observing how an approved medicine is used and how patients respond to it in their normal treatment. The information gathered will help doctors understand common side effects, how effective the treatment is, and how patients manage their condition while on venetoclax. It aims to improve care for future patients with CLL.
At a glance
What is this study about?
This study is focusing on a type of blood cancer called Chronic Lymphocytic Leukemia, or CLL. CLL is a slow-growing cancer that affects white blood cells. For people with CLL, one of the treatments available is a medication called venetoclax. This particular study isn't testing whether venetoclax works – it’s already an approved treatment. Instead, it's designed to see how venetoclax works for patients in their everyday lives, outside of a strict clinical trial setting. Think of it like watching how a car performs on different roads after it's been approved for sale, rather than just testing it on a perfect track.
The main goal is to understand the "real-life effectiveness" of venetoclax. This means doctors want to see how well it helps patients when used in typical hospital or clinic settings. They also want to learn about how doctors decide to use venetoclax and how patients manage their treatment over time. This includes looking at how common side effects are, how the dose might be changed, and how these factors affect a patient's health and well-being.
By gathering this information, researchers hope to get a clearer picture of how venetoclax performs in the broader patient population. This knowledge can then be used to advise doctors and patients, potentially leading to even better care and treatment strategies for people with CLL in the future.
Key takeaways
- This study aims to understand how venetoclax works for CLL patients in real-life settings.
- It's for people aged 18-99 who are starting venetoclax for CLL.
- Your treatment won't change; the study observes your regular care.
- Information gathered will help improve future care for CLL patients.
- Participation is voluntary and won't affect your treatment decisions.
- You cannot have been in another experimental CLL drug trial recently.
Who may be eligible?
This study is open to adults aged 18 to 99 who have been diagnosed with Chronic Lymphocytic Leukemia (CLL). To join, your doctor must have decided that starting treatment with venetoclax is the right choice for you, based on the standard guidelines for using this medicine.
It's important that your doctor feels they can look after you throughout the study period. You also need to be happy to have your health information collected and processed electronically for the study. You'll be given detailed information about the study both spoken and written, and you must agree to your data being used.
You cannot join this study if you've been taking part in another study for CLL that involved a new or experimental drug within the last 30 days before you were due to start venetoclax.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have a diagnosis of Chronic Lymphocytic Leukemia (CLL)?
- Has my doctor decided that venetoclax is the right treatment for me to start?
- Am I aged 18 years or older?
- Am I willing for my health information to be used for research?
- Have I avoided taking part in any experimental drug trials for CLL in the last month?
What does participation involve?
If you join this study, it largely involves documenting your standard care and treatment with venetoclax. There aren't any extra experimental treatments or procedures that you wouldn't normally receive. Your doctor will record information about your health, how you are responding to venetoclax, and any side effects you might experience, much like they already do during your regular check-ups. This information will be collected over the period that you are receiving your venetoclax treatment. The specific number of visits and tests will follow your usual treatment plan as decided by your doctor. There isn't a set total duration for your participation; it will align with the period your doctor plans to follow your venetoclax treatment.
Potential risks and benefits
Locations (60)
- CH Cannes - les Broussailles /ID# 201108Verified postcodeCannes, France
- CH CARCASSONNE - Antoine Gayraud /ID# 202530Verified postcodeCarcassonne, France
- CHU Clermont-Ferrand /ID# 170736Verified postcodeClermont, France
- Clinique Pole santé République /ID# 204658Verified postcodeClermont-Ferrand, France
- CH de la Haute-Saône - Vesoul /ID# 205150Verified postcodeVesoul, France
- CHU de RENNES /ID# 169944Verified postcodeRennes, France
- CHU de Besancon - Jean Minjoz /ID# 170721Verified postcodeBesançon, France
- Centre Hospitalier de Cornouaille /ID# 169937Verified postcodeQuimper, France
- CHU Limoges - Dupuytren 1 /ID# 200193Verified postcodeLimoges, France
- Institut Bergonie /ID# 170746Verified postcodeBordeaux, France
- CH Roubaix - Hopital Victor Provo /ID# 170909Verified postcodeRoubaix, France
- CHU Montpellier - Hopital Saint Eloi /ID# 200192Verified postcodeMontpellier, France
Common questions
What is Chronic Lymphocytic Leukemia (CLL)?
CLL is a slow-growing type of cancer that affects white blood cells, which are part of your immune system.
What is venetoclax?
Venetoclax is a medication used to treat certain types of blood cancers, including CLL.
Is this study testing a new medicine?
No, venetoclax is already an approved medicine. This study is about understanding its use and effects in everyday patient care.
Will my treatment change if I join this study?
No, your treatment plan will remain exactly as your doctor decides is best for your care. The study observes your normal treatment.
Do I have to take part?
No, joining is completely voluntary, and your decision won't affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.